PITTSBURGH--(EON: Enhanced Online News)--ALung Technologies, Inc., a leading developer of innovative respiratory assist devices, today announced it will showcase the Hemolung RAS next week at the 2013 Annual Congress of the European Society of Intensive Care Medicine (ESICM) in Paris. This announcement follows ALung’s recent hiring of its European team to support its commercial launch and global expansion.
“I am excited to have such a talented and experienced group of professionals join the ALung team”
During the ESICM congress, ALung will showcase the Hemolung RAS, a new extracorporeal carbon dioxide removal (ECCO2R) system that provides a dialysis-like alternative or supplement to mechanical ventilation, allowing a patient’s lungs to rest and heal in cases of acute respiratory failure.
Since receiving CE Mark approval earlier this year, ALung has worked to round out its European team, making several key hires. ALung has established direct commercial operations in Germany, France, and the United Kingdom, and is entering additional markets in conjunction with distribution partners.
ALung’s European leadership team includes:
- Jean-Michel Dutois, General Manager France, brings significant business development experience, having previously served as Country Manager France for Datascope Corporation;
- François Le Lan, Director EMEA Distribution, comes to ALung from Nonin Medical Inc. where he managed sales for western Europe. Based in France, Mr. Le Lan has over 20 years of medical device sales experience, primarily in ventilation;
- Garry Milner, General Manager UK, has worked with ALung since 2011, preparing the UK business unit. He comes to ALung following roles in sales and marketing at Respironics and Draeger Medical;
- Michael Remmers, General Manager Germany, comes to ALung from Philips Respironics where he was most recently Marketing Director Home Healthcare Solutions.
“I am excited to have such a talented and experienced group of professionals join the ALung team,” said Peter DeComo, Chairman and CEO of ALung. “Our new European managers are already hard at work executing our Hemolung Reference Center Program with clinicians across Europe. We are striving to make this technology the standard of care for treating patients with acute respiratory failure.”
The 2013 Annual Congress of the ESICM will be held from October 6 – 9 at the Palais des Congress de Paris, in Paris, France. ALung will showcase the Hemolung RAS at booth #2.20.
About the Hemolung RAS
The Hemolung RAS is a dialysis-like alternative or supplement to mechanical ventilation. The system provides Respiratory Dialysis®, a simple, minimally-invasive form of extracorporeal carbon dioxide removal (ECCO₂R) and has indications for use in patients with acute respiratory distress syndrome (ARDS) and acute exacerbation of chronic obstructive pulmonary disease (COPD). The device is approved for sale in Europe and Canada.
About ALung Technologies
ALung Technologies, Inc. is a Pittsburgh-based developer and manufacturer of innovative lung assist devices. Founded in 1997 as a spin-out of the University of Pittsburgh, ALung has developed the Hemolung RAS as a dialysis-like alternative or supplement to mechanical ventilation.
For more information, please visit http://www.alung.com.
This press release may contain forward-looking statements, which, if not based on historical facts, involve current assumptions and forecasts as well risks and uncertainties. Our actual results may differ materially from the results or events stated in the forward-looking statements, including, but not limited to, certain events not within the Company’s control. Events that could cause results to differ include failure to meet ongoing developmental and manufacturing timelines, changing GMP requirements, the need for additional capital requirements, risks associated with regulatory approval processes, adverse changes to reimbursement for the Company’s products/services, and delays with respect to market acceptance of new products/services and technologies. Other risks may be detailed from time to time, but the Company does not attempt to revise or update its forward-looking statements even if future experience or changes make it evident that any projected events or results expressed or implied therein will not be realized.